Insurance firm Aviva has co-led a round for Owlstone Medical, developer of a breathalyser that will help detect lung and colorectal cancer.
UK-based respiratory disease diagnostics developer Owlstone Medical has secured $15m in a funding round co-led by Aviva Ventures, the corporate venturing arm of insurance firm Aviva.
The round was co-led by venture capital firm Horizons Ventures and follows an investment of undisclosed size by Aviva in March 2017.
Owlstone Medical is developing an early disease diagnosis breathalyser called Breath Biopsy that is undergoing clinical trials in lung and colorectal cancer. It is also involved in a partnership with charity Cancer…
